Merck Prostate 365 - Combination therapies for mCRPC (Prostate Cancer)

What is the Purpose of this Study?

We are doing this study to find out if the study drug, pembrolizumab, is a safe and effective treatment for metastatic castrate-resistant prostate cancer when it is given in different combinations with other drugs. Pembrolizumab may work by increasing your immune system's response against a tumor.

What is the Condition Being Studied?

Metastatic Castrate-Resistant Prostate Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with a type of metastatic castrate-resistant prostate cancer called "neuroendocrine carcinoma"
  • Have previously been treated with a drug called docetaxel

For more information about who can join this study, please contact the study team at julia.hurrelbrink@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Be assigned to take the study drug, pembrolizumab, in combination with lenvatinib, or MK-7684, or carboplatin + etoposide
  • Have blood draws
  • Give urine samples
  • Have imaging scans (CT and/or MRI)

Pembrolizumab, MK-7684, etoposide, and carboplatin are all drugs taken intravenously (through a needle in a vein in your arm). Lenvatinib is a pill that you take by mouth.

Study Details

Full Title
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Principal Investigator
Assistant Professor of Medicine
Protocol Number
IRB: PRO00081276
NCT: NCT02861573
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate